Torrent Pharmaceuticals Limited (TORNTPHARM) — Financial Results Announcement

Investor Takeaways

Overall Tone: Positive

Key Financial Highlights

What Changed

The filing reveals consolidated financial results for FY26, with revenue of ₹13,980 crores and net profit of ₹2,138 crores, driven by the acquisition of JB Pharma effective January 21, 2026. Revenue growth of 21% YoY was led by a 42% YoY increase in Q4 revenue to ₹4,197 crores, supported by strong performance in Brazil and the US markets. The acquisition contributed to exceptional items of ₹66 crores and non-comparable figures. The company proposed a final dividend of ₹9 per share (180% payout) and announced a ₹5,000 crore Qualified Institutional Placement (QIP). The auditor issued an unmodified opinion on the consolidated financials, confirming compliance with SEBI regulations and Indian Accounting Standards. The AGM scheduled for June 2026 will seek shareholder approval for the dividend and capital raise. Record date for dividend eligibility is May 29, 2026, with payment expected around June 25, 2026. The filing also notes that the company’s current fundamentals include a market capitalization of ₹1,49,108.91 crores and a P/E ratio of 80.06.

Peer Comparison

Torrent Pharmaceuticals trades at a significant premium to Sun Pharmaceutical Industries Limited and Divi's Laboratories Limited in terms of P/E ratio, reflecting market expectations around growth from the JB Pharma acquisition and international expansion.

Risks & Concerns

Quarterly Trend

The quarterly trend shows stable revenue and profit levels in the fiscal year preceding FY26, with operating profit margins remaining relatively consistent around 32%. The FY26 results reflect a significant inflection point due to the acquisition and associated growth in international markets.